Abstract: A method of detecting or diagnosing squamous cancers in a sample from a subject, including isolating extracellular vesicles from the sample, wherein the extracellular vesicles are cancer specific.

Abstract: An enhanced delivery vehicle for a treating agent includes a base delivery vehicle, which is adapted for carrying a treating agent for uptake thereof by a target cell, and an enhancing component. The enhancing component may be at least one energy rich substance, at least one agent which increases production of at least one energy rich substance in the target cell, or a combination thereof. The enhancing component enhances the uptake of the base delivery vehicle by the target cell. Non-limiting examples of the base delivery vehicle include exosomes, microvesicles, apoptotic bodies, oncosomes, extracellular vesicles, microparticles, liposomes, and nanoparticles. In one embodiment, the enhancing component is an exosome engineered to be substantially devoid of endogenous nucleic acids. In one embodiment, the enhancing component is at least one energy rich substance including, but not limited to, ATP, NADH, NADPH, FADH2, acetyl CoA, glucose, pyruvate, GTP, CTP, and UTP.

Abstract: The present disclosure relates to methods and compositions for preventing and/or treating liver fibrosis, liver cancer, and/or liver disease. In particular, the present disclosure relates methods and compositions which to decrease or inhibit microRNA found to be upregulated in liver fibrosis, liver cancer, and/or liver disease, or increase or activate microRNA found to be downregulated in liver fibrosis, liver cancer and/or liver disease. The present disclosure also relates to the use of engineered exosomes or extracellular vesicles in the methods and compositions for targeted delivery of the agents to the liver.

Abstract: The compositions for enhancing nucleic acid therapeutics are used in the treatment or prevention of diseases or conditions. The compositions improve the use of nucleic acid therapeutics with the use of enhancing or stabilizing elements, such as RNA-induced silencing complex (RISC) proteins. The compositions include at least one nucleic acid therapeutic or a polynucleotide encoding at least one nucleic acid therapeutic; at least one enhancing or stabilizing element, mutant, variant or modified form thereof, or a polynucleotide encoding at least one enhancing or stabilizing element, mutant, variant or Modified form thereof; and a delivery vehicle, where the delivery vehicle may be exosomes, microvesicles, apoptotic bodies, oncosomes, microparticles, extracellular vesicles, liposomes, nanoparticles, plasmids or vectors.

Abstract: Methods of preparing tissues for treatment or imaging and for treating or imaging tissues in a subject in which therapeutic or imageable molecules operably associated with a heat-inducible promoter and an HSP-inducing molecule are administered to the subject.

Abstract: Radiolabeled compounds of Formula I are described. Processes for radiolabeling the compounds are described. Methods for radioactive imaging using the compounds are also described.

Abstract: Methods and diagnostic compositions for detection of amyloid deposits using a chimeric (e.g., mouse-human) antibody or antigen-binding fragment thereof linked to a detectable label are disclosed.

Abstract: A method of increasing blood-brain barrier permeability of selected brain tissue in a subject in need thereof is carried out by: (a) parenterally administering to the subject stem cells that migrate to the brain tissue, the stem cells containing a recombinant nucleic acid, the recombinant nucleic acid comprising a nucleic acid encoding a barrier-opening protein or peptide operably associated with a heat-inducible promoter; and then (b) selectively heating the selected brain tissue sufficient to induce the expression of the barrier-opening protein or peptide in an amount effective to increase the permeability of the blood-brain barrier in the selected brain tissue. Nucleic acids, vectors, stem cells and compositions useful for carrying out such methods are also described.

Abstract: A method for stimulating a immune response against IL-13R?2 in a subject having or at risk for developing a disease having cells expressing IL-13R?2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13R?2 in the subject. A composition for stimulating a immune response against IL-13R?2 in a subject having or at risk for developing a disease having cells expressing IL-13R?2 includes an isolated agent that can stimulate immune response against IL-13?2.

Abstract: A method for stimulating a immune response against IL-13R?2 in a subject having or at risk for developing a disease having cells expressing IL-13R?2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13R?2 in the subject. A composition for stimulating a immune response against IL-13R?2 in a subject having or at risk for developing a disease having cells expressing IL-13R?2 includes an isolated agent that can stimulate immune response against IL-13?2.

Abstract: A method for stimulating a immune response against IL-13R?2 in a subject having or at risk for developing a disease having cells expressing IL-13R?2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13R?2 in the subject. A composition for stimulating a immune response against IL-13R?2 in a subject having or at risk for developing a disease having cells expressing IL-13R?2 includes an isolated agent that can stimulate immune response against IL-13?2.

Abstract: A method for stimulating a immune response against IL-13R?2 in a subject having or at risk for developing a disease having cells expressing IL-13R?2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13R?2 in the subject. A composition for stimulating a immune response against IL-13R?2 in a subject having or at risk for developing a disease having cells expressing IL-13R?2 includes an isolated agent that can stimulate immune response against IL-13?2.

Abstract: A method for stimulating a immune response against IL-13R?2 in a subject having or at risk for developing a disease having cells expressing IL-13R?2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13R?2 in the subject. A composition for stimulating a immune response against IL-13R?2 in a subject having or at risk for developing a disease having cells expressing IL-13R?2 includes an isolated agent that can stimulate immune response against IL-13?2.

Abstract: A method for stimulating a immune response against IL-13R?2 in a subject having or at risk for developing a disease having cells expressing IL-13R?2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13R?2 in the subject. A composition for stimulating a immune response against IL-13R?2 in a subject having or at risk for developing a disease having cells expressing IL-13R?2 includes an isolated agent that can stimulate immune response against IL-13?2.

Abstract: A method for stimulating a immune response against IL-13R?2 in a subject having or at risk for developing a disease having cells expressing IL-13R?2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13R?2 in the subject. A composition for stimulating a immune response against IL-13R?2 in a subject having or at risk for developing a disease having cells expressing IL-13R?2 includes an isolated agent that can stimulate immune response against IL-13?2.

Abstract: A method for stimulating a immune response against IL-13R?2 in a subject having or at risk for developing a disease having cells expressing IL-13R?2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13R?2 in the subject. A composition for stimulating a immune response against IL-13R?2 in a subject having or at risk for developing a disease having cells expressing IL-13R?2 includes an isolated agent that can stimulate immune response against IL-13?2.

Abstract: A method for stimulating a immune response against IL-13R&agr;2 in a subject having or at risk for developing a disease having cells expressing IL-13R&agr;2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13R&agr;2 in the subject. A composition for stimulating a immune response against IL-13R&agr;2 in a subject having or at risk for developing a disease having cells expressing IL-13R&agr;2 includes an isolated agent that can stimulate immune response against IL-13&agr;2.